Skip to main content

Table 1 Hypercoagulability study in association with post-transplant thromboses

From: Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients

  With thrombosis post-transplant (26 Cases) Without thrombosis post-transplant (267 Cases) Significance
RECIPIENT STUDY    
Platelets (×109/L) 327.27 ± 88.0 264.89 ± 73.7 p < 0.001
PA (%) 101.96 ± 21.5 101.79 ± 16.4 p = 0.962
APTT (seconds) 31.24 ± 6.1 31.08 ± 4.4 p = 0.866
TT (seconds) 13.8 ± 2.2 14.22 ± 1.9 p = 0.301
Fibrinogen (mg/dL) 327.3 ± 88.7 264.89 ± 73.7 p < 0.001
AT (U/dL) 107.57 ± 18.3 99.57 ± 15.3 p = 0.013
PC chromogenic (U/dL) 61.34 ± 41.9 74.69 ± 39.8 p = 0.069
PC anticoagulant (U/dL) 94.68 ± 18.99 102.61 ± 27.5 p = 0.065
PS free antigen (U/dL) 84.0 ± 12.7 77.85 ± 14.2 p = 0.038
PS functional (U/dL) 95.4 ± 24.9 83.44 ± 22.3 p = 0.011
PS total (U/dL) 90.0 ± 9.0 93.9 ± 18.3 p = 0.716
Factor VIII (UI/dL 168.77 ± 60.8 153.95 ± 56.9 p = 0.209
ACA IgG (uFl) 5.84 ± 5.0 7.56 ± 16.49 p = 0.605
ACA IgM (uFl) 11.24 ± 18.64 9.3 ± 14.68 p = 0.539
Plasma homocysteine (μmoles/L) 13.79 ± 3.35 14.31 ± 8.7 p = 0.585
Factor V Leiden mutation (N°) (heterozygous) in recipient 1/26 6/264 p = 0.618
Prothrombin 20210A mutation (N°) (heterozygous) in recipient 0/26 13/264 p = 0.247
C677T MTHFR mutation (N°) (wild type/heterozygous/homozygous) in recipient 13/8/4 102/117/37 p = 0.402
APCR 2.86 ± 0.51 2.92 ± 0.51 p = 0.582
DONOR STUDY    
Factor V Leiden mutation (N°) (heterozygous) in donor 0/26 4/196 p = 0.454
Prothrombin 20210A mutation (N°) (heterozygous) in donor 1/26 6/194 p = 0.865
C677T MTHFR mutation (N°) (wild type/heterozygous/homozygous) in donor 9/14/3 63/101/28 p = 0.915
  1. PA (pro-thrombin activity); APTT (activated partial thromboplastin time); TT (thrombin clotting time); AT (anti-thrombin); PC (protein C); PS (protein S); ACA (anticardiolipin antibody); APCR (activated protein C resistance); (MTHFR) 5,10-methylenetetrahydrofolate reductase.